Why and when aspergillosis first appears in cystic fibrosis patients?
Thursday, February 15, 2018 - 10:48Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

The Human Lung and Aspergillosis: You are what you Breathe in?
Thursday, February 15, 2018 - 10:30Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Managing breakthrough invasive aspergillosis
Thursday, February 15, 2018 - 10:19Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Recent Advances in Diagnosis and Treatment of Allergic Aspergillosis
Thursday, February 15, 2018 - 10:18Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Pulmatrix doses first patient in Ph1 Pulmazole trial
Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole. The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

8th Advances Against Aspergillosis Conference Round-Up
Mon, 02/05/2018 - 14:02News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 5, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Announcing the Launch of the World Aspergillosis Day Feb 1st
Wed, 01/31/2018 - 16:21News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Announcing the Launch of World Aspergillosis Day Feb 1st
Wed, 01/31/2018 - 16:21News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Global health improvement targets announced on World Aspergillosis Day
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Global health improvement targets announced on World Aspergillosis Day Feb. 1st, 2018
(Goodwork) Aspergillosis, lung and sinus disease caused by the fungus Aspergillus, affects around 15 million people and kills over 1 million each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial
The UK Medicines and Healthcare Products Regulatory Agency has given Pulmatrix (NSDQ:PULM) the go-ahead to launch its first-in-human study for an inhaled formulation of the anti-fungal drug, itraconazole. The company is evaluating its drug, Pulmazole, as a treatment for allergic bronchopulmonary aspergillosis in patients with asthma. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Invasive Aspergillosis in Heart Transplant Recipients
Wed, 01/03/2018 - 12:08News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 3, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news